Two mitochondrial group I introns in a metazoan, the sea anemone Metridium senile: one intron contains genes for subunits 1 and 3 of NADH dehydrogenase.

Mitochondrial genes for cytochrome c oxidase subunit I (COI) and NADH dehydrogenase subunit 5 (ND5) of the sea anemone Metridium senile (phylum Cnidaria) each contain a group I intron. This is in contrast to the reported absence of introns in all other metazoan mtDNAs so far examined. The ND5 intron is unusual in that it ends with A and contains two genes (ND1 and ND3) encoding additional subunits of NADH dehydrogenase. Correctly excised ND5 introns are not circularized but are precisely cleaved near their 3' ends and polyadenylylated to provide bicistronic transcripts of ND1 and ND3. COI introns, which encode a putative homing endonuclease, circularize, but in a way that retains the entire genome-encoded intron sequence (other group I introns are circularized with loss of a short segment of the intron 5' end). Introns were detected in the COI and ND5 genes of other sea anemones, but not in the COI and ND5 genes of other cnidarians. This suggests that the sea anemone mitochondrial introns may have been acquired relatively recently.

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigrostriatal dopaminergic pathway damage similar to that observed in Parkinson disease (PD). To study the role of NO radical in MPTP-induced neurotoxicity, we injected MPTP into mice in which nitric oxide synthase (NOS) was inhibited by 7-nitroindazole (7-NI) in a time- and dose-dependent fashion. 7-NI dramatically protected MPTP-injected mice against indices of severe injury to the nigrostriatal dopaminergic pathway, including reduction in striatal dopamine contents, decreases in numbers of nigral tyrosine hydroxylase-positive neurons, and numerous silver-stained degenerating nigral neurons. The resistance of 7-NI-injected mice to MPTP is not due to alterations in striatal pharmacokinetics or content of 1-methyl-4-phenylpyridinium ion (MPP+), the active metabolite of MPTP. To study specifically the role of neuronal NOS (nNOS), MPTP was administered to mutant mice lacking the nNOS gene. Mutant mice are significantly more resistant to MPTP-induced neurotoxicity compared with wild-type littermates. These results indicate that neuronally derived NO mediates, in part, MPTP-induced neurotoxicity. The similarity between the MPTP model and PD raises the possibility that NO may play a significant role in the etiology of PD.

Fast-timing study of the l-forbidden 1/2(+) -> 3/2(+) M1 transition in Sn-129

The levels in Sn-129 populated from the beta(-) decay of In-129 isomers were investigated at the ISOLDE facility of CERN using the newly commissioned ISOLDE Decay Station (IDS). The lowest 1/2(+) state and the 3/2(+) ground state in 129Sn are expected to have configurations dominated by the neutron s(1/2) (l = 0) and d(3/2) (l = 2) single-particle states, respectively. Consequently, these states should be connected by a somewhat slow l-forbidden M1 transition. Using fast-timing spectroscopy we havemeasured the half-life of the 1/2(+) 315.3-keV state, T-1/2 = 19(10) ps, which corresponds to a moderately fast M1 transition. Shell-model calculations using the CD-Bonn effective interaction, with standard effective charges and g factors, predict a 4-ns half-life for this level. We can reconcile the shell-model calculations to the measured T-1/2 value by the renormalization of the M1 effective operator for neutron holes.

Insight into the immobilization of ionic liquids on porous carbons

Very different carbon materials have been used as support in the preparation of supported ionic liquid phase samples (SILP). Some of them have been oxidized, either strongly (with ammonium persulfate solution) or weakly (with air at 300 ��C, 2 h). The purpose is to establish which properties of the supports (e.g., porosity -volume and type-, surface area, oxygen surface chemistry and morphology) determine the IL adsorption capacity and the stability (immobilization) of the supported IL phase. The ionic liquid used in this work is 1-butyl-3-methyl-imidazolium hexafluorophosphate ([bmim][PF6]). For each support, samples with different amounts of ionic liquid have been prepared. The maximum IL that can be loaded depends mainly on the total pore volume of the supports. For comparable pore volumes, the porosity type and the oxygen surface content have no influence on the IL loading. The supported IL fills most of the pores, leaving some blocked porosity. The stability of the supported IL phase (especially important for its subsequent use in catalysis) has been tested in water under general hydrogenation conditions (60 ��C and 10 bar H2). In general, leaching is low but it increases with the amount of IL loaded and with the oxidation treatments of the supports.

Clarke, Daniell, autographed letter signed to Hugh Caukin; Windsor, Conn., 1 side (3 pages), 1652 February 11

Correspondence describing the tooth and gum decay of several of his children. Clarke requests that Caukin show his letter to John Winthrop and solicit his advice regarding potential courses of treatment.

Sherman, John, 1613-1685, autographed letter signed to John Winthrop; Watertown, Mass., 1 side (3 pages), 1663 June 30

Correspondence describing a hernia Sherman was suffering, and asking for Winthrop's advice and a "little of [your] red powder."

Stone, Sam, 1602-1663, autographed letter signed to John Winthrop; Hartford, 1 side (3 pages), 1652 February 1652

Correspondence seeking advice from Winthrop about his 23-week-old son, who was suffering from jaundice and a cough. Stone writes the course of treatment for the infant, on the advice of a Mrs. Hooker, had included barbaric bark boiled in beer with saffron twice daily, as well as turmeric. He also administered Winthrop's purging powder, and Stone asks if he should continue giving the powder and at what dose, and if there is any other medicines Winthrop would prescribe.

Ward, George, autographed letter signed to John Winthrop; Brainford, 1 side (3 pages), 1652 June 15

Correspondence seeking advice on treatment of a urinary condition.

Winthrop, Robert Charles, 1809-1894, autographed letter signed to James Read Chadwick; Boston, 1 side (3 pages), 1879 January 29

Correspondence regarding the donation of several collections to the Boston Medical Library, including the John Winthrop papers

Synthesis of xanthone-1,2,3-triazole dyads

Xanthones and 1,2,3-triazoles are known to exhibit several biological, pharmacological and biocidal properties[1]. The potential applications of these two classes of heterocycles led us to develop new strategies to synthesize xanthone-1,2,3-triazole dyads, aiming to get potentially improved therapeutic agents[2]. With this rational in mind we designed and synthesized novel chromone derivatives 1a-d to be used as building motifs and to explore the reactivity of the two unsaturated systems (the diene and the alkyne). In the present communication we will present a new synthetic route towards the synthesis of xanthone-1,2,3-triazole dyads 7a-d using consecutively the azide-alkyne Huisgen 1,3-dipolar cycloaddition and Diels-Alder reaction. Our approach involves the synthesis chromone-triazole derivatives 2a-d using the reaction of 1a-d with sodium azide, followed by the methylation of the NH of the triazole moiety. The methylation afforded three isomers 3a-d, 4a-d and 5a-d, as expected. The major isomers 3a-d were used in the Diels-Alder reaction with N-methylmaleimide, and the adducts obtained 6a-d were oxidized to afford the xanthone-1,2,3-triazole dyads 7a-d. All the synthetic details as well as the structural characterization (by 1D and 2D NMR studies) of the new synthesised compounds will be presented and discussed.

Recent developments in the synthesis of novel xanthone-1,2,3-triazole dyads

The development of multi-target drugs for treating complex multifactorial diseases constitutes an active research ield. This kind of drugs has gained much importance as alternative strategy to combination therapy (���cocktail drugs���).1 A common way to design them brings together two different pharmacophores in one single molecule (so-called dyads). Following this idea and being aware that xanthones2 and 1,2,3-triazoles3 possess important pharmacological properties, we combined these two heterocycles in one molecule to create new dyads with improved therapeutic potential. In this work, new xanthone-1,2,3-triazole dyads were prepared from novel (E)-2-(4-arylbut-1-en-3-yn-1-yl)chromones by two different approaches to evaluate their eficiency and sustainability. Both methodologies involved Diels-Alder reactions to build the xanthone core, which were optimized using microwave irradiation as alternative heating method, and 1,3-dipolar cycloadditions to insert the 1,2,3-triazole moiety (Figure 1).4 All final and intermediate compounds were fully characterized by 1D and 2D NMR techniques.